Publications by authors named "S Shimoji"
Background: Wilms' Tumor (WT1) mRNA is a non-specific marker of measurable residual disease in acute myeloid leukemia (AML). Few studies have focused on the prognostic value of WT1 mRNA after initial remission induction of patients with AML who have received transplant treatments.
Objective: Thus, we retrospectively analyzed the clinical features and prognostic impact of WT1 mRNA reduction in patients with AML after initial remission induction at our hospital.
Japan has resumed its health technology assessment to decide how to reduce high-cost drug prices. While drug price rules in Japan are comprehensive, they do not necessarily capture differences in product characteristics. This study examined the drug price revision strategy in Japan using migraine treatment with triptans as an example.
View Article and Find Full Text PDFA case report of fatal anaphylaxis on first exposure to rasburicase just before lymphoma treatment.
Allergy Asthma Clin Immunol
October 2024
Article Synopsis
- * A case involving a 71-year-old woman with lymphoma resulted in fatal anaphylactic shock following her first dose of rasburicase, leading to multiple complications including heart compression and significant bleeding.
- * This case highlights that while it’s uncommon, rasburicase can cause deadly anaphylaxis even in patients who have not previously been exposed to the drug.
Article Synopsis
- The study investigates the effects of Epstein-Barr virus (EBV) reactivation in 121 patients who underwent allogenic hematopoietic stem cell transplantation (allo-HSCT), focusing on the clinical characteristics and outcomes related to EBV viral load.
- Patients were categorized based on their EBV DNA levels, with 50 showing levels above 1000 copies/mL and 71 below that threshold, revealing that higher EBV levels were linked to specific clinical factors like graft versus host disease (GVHD).
- Results indicated that there was no significant difference in overall survival (OS) and disease-free survival (DFS) between the two groups, but rapid reduction of immunosuppressants in patients with high EBV levels showed